Emergency Sickle Cell Support Service Extended at Royal London Hospital After Patient Campaign

A specialist emergency service for people living with sickle cell disease in east London will continue after a successful trial and strong support from patients and advocacy groups. Health officials confirmed that the Royal London Hospital in Whitechapel will extend the programme following positive results from its pilot phase.

The service was first introduced as a temporary initiative between September and January. It created a same day emergency unit designed to treat sickle cell patients quickly without requiring them to enter the traditional Accident and Emergency department. The aim was to provide faster specialist care for people experiencing painful sickle cell crises, which often require immediate medical attention.

Hospital leaders say the trial showed clear improvements in how patients received treatment. By directing individuals to a dedicated specialist unit, medical teams were able to assess and treat symptoms more rapidly while also reducing pressure on busy emergency departments. Patients also benefited from staff who have specific expertise in managing the condition.

Sickle cell disease is a lifelong genetic blood disorder that can cause severe pain episodes, infections and other serious complications. It mainly affects people of African and Caribbean heritage. Health experts say better access to specialist care is essential because delayed treatment during a crisis can lead to serious health risks.

According to Barts Health NHS Trust, which manages the Royal London Hospital, the region has one of the largest sickle cell patient populations in the country. Around one in seven people in the United Kingdom living with the condition are based in north east London and Essex. The trust’s hospitals currently provide care for roughly nine hundred patients diagnosed with sickle cell disease.

In response to the growing demand for improved services, the trust invested two million pounds last year to strengthen emergency care and community support programmes. Officials say the funding helped launch the dedicated emergency pathway and improve patient outcomes while also addressing long standing health inequalities.

The hospital has now confirmed an additional investment of one million pounds for the 2026 to 2027 financial year. The funding will help expand support services and improve community based care for people living with the condition. Plans include a network of consultant led clinics where patients can receive specialist advice, monitoring and treatment in one location.

Medical leaders say the next stage will focus on refining the emergency care model while keeping the core objective of fast specialist treatment. While the service may operate under a different structure in the future, hospital officials say the goal remains ensuring that patients experiencing sickle cell crises receive immediate care from experienced clinical teams.

Advocacy groups representing patients have welcomed the decision to extend the service. They say the pilot demonstrated the importance of having dedicated crisis pathways that prioritise rapid treatment and specialist knowledge.

Community representatives also highlighted how patient feedback played a major role in shaping the service. Many families and individuals living with the condition shared their experiences during the trial period, helping health authorities understand the impact of the specialist care model and why it should continue.